Antibody-Drug Conjugates, Lung Cancer Late-Breaker to Take Center Stage at ASCO
“The American Society of Clinical Oncology 2023 annual meeting, which kicks off Friday in Chicago, will feature one of the hottest emergent areas of cancer treatment—antibody-drug conjugates. Biopharma companies are betting big on ADCs and the technology from BioNTech and Merck—among others—are the subject of several high-profile ASCO abstracts.”

An Oncologist’s Advice for Finding a Path Forward When Living With Lung Cancer
“When a person who has been faced with a diagnosis of non-metastatic lung cancer (cancer that has not yet spread) finally completes their treatment or has surgery, they may feel excitement, joy and hope for the future. They often celebrate with their friends and family, and share a collective sigh of relief. But for many people, these feelings can soon give way to the fear that their cancer may come back.”

One Million People Complete Lifesaving Quiz for Lung Cancer Screening
“CHICAGO, June 1, 2023 /PRNewswire/ — The American Lung Association today announced it reached an important milestone in the efforts to end lung cancer. As a part of the “Saved by the Scan” campaign, more than one million people, 1,051,303 as of April 2023, have completed an online quiz to determine if they are eligible for lifesaving lung cancer screening. Twenty-five percent of those who have taken the quiz since the campaign’s inception were found to be high-risk for lung cancer and eligible for screening.”

Lung Cancer: Types, Differences, and Survival Rates
“Lung cancer accounts for 12.4% of all cancers and is the most prevalent cancer worldwide. In the United States, lung cancer has the highest cancer-associated death rate. Although smoking is the leading cause, 10–20% of lung cancers occur in non-smokers.”

Lung cancer pill cuts risk of death by half, says ‘thrilling’ study
“A pill taken once a day cuts the risk of dying from lung cancer by half, according to “thrilling” and “unprecedented” results from a decade-long global study.”

‘Extraordinary’ survival data for lung cancer patients is seen as boost for AstraZeneca drug
“CHICAGO — Giving the AstraZeneca drug Tagrisso to patients with non-small cell lung cancer who have had their tumors removed reduced the risk of death by 51%, researchers said Sunday.”

Ground-breaking warhead drug means the cure for lung cancer may FINALLY be on the horizon
“Three new advances are set to transform lung cancer treatment – turning the tide on a disease that is often considered a death sentence. Someone in the UK is diagnosed with lung cancer every ten minutes – amounting to roughly 50,000 new patients each year – and just a quarter survive five years. Some 35,000 die of it annually, making it our biggest cancer killer.”

IARC researchers identify early blood protein markers of lung cancer that may improve early detection
“Researchers from the International Agency for Research on Cancer (IARC) and partner institutions have identified protein markers in blood samples that are associated with future lung cancer diagnosis, and have developed an algorithm based on these markers to predict future lung cancer cases. These important complementary findings were published today as separate articles in Nature Communications and the Journal of the National Cancer Institute.”

Medical student awarded grant to study lung cancer therapies
“Matthew Lara receives the 2023 Daniel T. O’Connor, M.D. Memorial Research Grant”

Incidence of Colorectal, Lung, and Breast Cancers May Be Rising Due to COVID-19–Related Screening Delays
“Delays in cancer screenings during the COVID-19 pandemic may have resulted in lower reported incidences of colorectal, lung, and breast cancers, reflecting potentially high rates of undiagnosed cancer and later-stage diagnoses, according to a new study published by Romatoski et al in the Journal of the American College of Surgeons. The findings demonstrated that there may be a significant increase in cancer cases that could have been caught earlier with screenings, placing an increased burden on an already strained health-care system.”

FDA Gives Priority Review to Repotrectinib in Advanced ROS1+ NSCLC
“The FDA has granted priority review to a new drug application (NDA) for the tyrosine kinase inhibitor (TKI) repotrectinib (TPX-0005, BMS-986472) in the treatment of patients with ROS1-positive locally advanced or metastatic non–small cell lung cancer (NSCLC), according to a press release from Bristol Myers Squibb.”

Long-term Benefit of Amivantamab Continues in Postplatinum NSCLC
“Long-term data from the CHRYSALIS trial (NCT02609776) continued to demonstrate clinical benefit for amivantamabvmjw (Rybrevant), according to findings presented at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.”